Serum antigen detection in the diagnosis, treatment, and follow-up of neurocysticercosis patients

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 94, Issue 6, 2000, Pages 673-676

  Garcia, H H ^a,b   Parkhouse, R M E ^c   Gilman, R H ^a,d   Montenegro, T ^a   Bernal, T ^e   Martinez, S M ^b   Gonzalez, A E ^e   Tsang, V C W ^f   Harrison, L J S ^g  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b INSTITUTO NACIONAL DE CIENCIAS NEUROLÓGICAS   (Peru)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSIDAD NACIONAL MAYOR DE SAN MARCOS   (Peru)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Albendazole; Antigen detection; Chemotherapy; ELISA; Follow up; Neurocysticercosis; Peru; Taenia solium

Indexed keywords

ALBENDAZOLE; DEXAMETHASONE; GLYCOPROTEIN; MONOCLONAL ANTIBODY; PARASITE ANTIGEN;

ADULT; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTICERCUS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; NEUROCYSTICERCOSIS; NONHUMAN; PARASITE IDENTIFICATION; PERU; REFRACTORY PERIOD; SAMPLING; TREATMENT OUTCOME;

EID: 0033659834     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(00)90228-1     Document Type: Article

References (20)

1. Human cysticercosis: Risk factors associated with circulating serum antigens in an open community of San Luis Potosi, Mexico
2. The magnitude of the disease burden from neurocysticercosis in a developing country. The Cysticercosis Working Group in Peru
3. Determination of circulating antigen in cysticercosis patients using McAb-based ELISA
4. Detection of antigens of larval Taenia solium in the cerebrospinal fluid of patients with the use of HPLC and ELISA
5. Human neurocysticercosis: Comparison of enzyme immunoassay capture techniques based on monoclonal and polyclonal antibodies for the detection of parasite products in cerebrospinal fluid
6. Immunochemical detection of antigens of larval Taenia solium and anti-larval antibodies in the cerebrospinal fluid of patients with neurocysticercosis
7. Identification of Taenia solium antigens in cerebrospinal fluid and larval antigens from patients with neurocysticercosis
8. Controversies in the management of cysticercosis
9. Discrepancies between cerebral computed tomography and Western blot in the diagnosis of neurocysticercosis. The Cysticercosis Working Group in Peru
10. Serological evolution of neurocysticercosis patients after antiparasitic therapy
11. Albendazole therapy for neurocysticercosis: A prospective double blind trial comparing 7 vs. 14 days of treatment
12. A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis
13. Specific detection of circulating surface/secreted glycoproteins of viable cysticerci in Taenia saginata cysticercosis
14. Edema associated with calcified lesions in neurocysticercosis
15. Detection of Cysticercus cellulosae antigens in cerebrospinal fluid by dot enzyme-linked immunosorbent assay (dot-ELISA) and standard ELISA
16. An enzyme-linked immunoelectrotransfer blot assay and glycoprotein antigens of diagnosing human cysticercosis (Taenia solium)
17. A MAb-based ELISA for detecting circulating antigen in CSF of patients with neurocysticercosis
18. Neurocysticercosis: A major cause of neurological disease worldwide